Liraglutide vs. Semaglutide: Same Drug Class, Different Verdict

Wait — is Ozempic semaglutide, or something else? Where does Wegovy fit?

Semaglutide is the molecule, not a single product. It's sold under three different brand names, each tied to a different FDA approval: Ozempic, approved for type 2 diabetes, Wegovy, approved at a higher dose for chronic weight management, and Rybelsus, an oral tablet approved for diabetes. All three ship the same active ingredient from Novo Nordisk. A compounding pharmacy can also prepare semaglutide directly, outside any of those three brand names, under a narrower legal pathway covered further down this page.

Liraglutide works the same way, structurally. It's an older, separate molecule sold as Victoza for diabetes and Saxenda for weight management — same manufacturer, same GLP-1 drug class, different molecule entirely from semaglutide. So the honest short answer to 'is Ozempic just semaglutide' is yes, and the honest short answer to 'is liraglutide the same thing' is no. Two molecules, four historic brand names between them, one drug class.

So what's the real difference between semaglutide and liraglutide?

Liraglutide came first. Victoza reached the US market in 2010 for type 2 diabetes, and Saxenda followed in 2014 as the first liraglutide brand approved specifically for weight management. Semaglutide is the newer molecule built on the same basic mechanism — both drugs mimic GLP-1, a gut hormone that slows digestion, boosts insulin release after meals, and quiets appetite signaling in the brain. Ozempic arrived in 2017 for diabetes, and Wegovy followed in 2021 for weight loss, mirroring liraglutide's own diabetes-then-obesity approval pattern about seven years apart.

The structural difference between the two molecules comes down to how long each one stays active in the body. Liraglutide has a half-life of roughly 13 hours, which is why it needs a daily injection to keep blood levels steady. Semaglutide's chemical modifications stretch that out to about a week, which is what makes once-weekly dosing possible. That single difference in molecular design is the underlying reason semaglutide could be engineered for a higher effective dose without daily injections — and it's the mechanistic seed of most of what separates the two drugs on the results below.

Which one actually works better for weight loss?

This is one of the rare GLP-1 comparisons with a genuine head-to-head randomized trial behind it, rather than two separate studies compared after the fact. STEP 8, published in JAMA in 2022, put adults with overweight or obesity — none of them living with diabetes — on either weekly semaglutide at 2.4mg or daily liraglutide at 3.0mg for 68 weeks, then measured both groups under the same protocol. Mean body weight fell by about 15.8% on semaglutide and about 6.4% on liraglutide — semaglutide's average result ran more than double liraglutide's in that trial.

That head-to-head result lines up with what each drug's own approval trials found separately: liraglutide's SCALE trial reported roughly 8% weight loss at 56 weeks, and semaglutide's STEP trials have reported figures in the neighborhood of 15% at 68 weeks. Because STEP 8 tested both drugs directly against each other rather than relying on that cross-trial comparison, it's the stronger evidence of the two — and it's also the single biggest reason liraglutide's clinical use has faded as semaglutide (and more recently tirzepatide) became available. These are still trial averages, not a guarantee for any one person; individual results vary with dose, adherence, and physiology.

Semaglutide pills vs. injections — and where does liraglutide fit?

Liraglutide is injection-only. Both Victoza and Saxenda come as daily self-injected pens, and there's no FDA-approved liraglutide tablet on the market. If avoiding injections is a hard requirement, liraglutide isn't the molecule that gets you there.

Semaglutide has more range here. The weekly injection is what most people picture — Ozempic or Wegovy pens, or a compounded weekly injection from a telehealth pharmacy. But Rybelsus is an FDA-approved oral semaglutide tablet, taken daily on an empty stomach with a small amount of water and a wait before eating anything else. Its real dosing ladder runs 3mg, 7mg, and 14mg — worth flagging directly, since '5mg' and '10mg' aren't actual semaglutide doses in either the tablet or the injectable form; injectable semaglutide (Ozempic or Wegovy) is dosed from 0.25mg up to 2.4mg weekly instead. As of May 2026, Novo Nordisk also began marketing Rybelsus under the name 'the Ozempic pill' at NovoCare's cash-pay pricing, which is a rebrand of the same tablet rather than a new drug. Compounded oral semaglutide also exists as sublingual troches through some telehealth pharmacies, though those are compounded formulations with different absorption than a swallowed tablet, not a copy of Rybelsus.

Which costs less — semaglutide or liraglutide, brand or compounded?

Semaglutide wins on price at almost every tier, and the compounded and insured tiers narrow the gap the most. The table above lines up the comparable options; the sections below walk through what's actually behind each number.

Compounded semaglutide — and why there's no compounded-liraglutide row here

The cheapest verified sustained option on this page is compounded semaglutide through Fridays, running $150 to $249 a month depending on how far in advance you prepay — $249 month-to-month, dropping toward $150 on a full annual commitment. We deliberately left compounded liraglutide off the table: despite liraglutide injection technically still showing up on federal drug-shortage tracking for some presentations, we couldn't find a legitimate telehealth provider currently offering compounded liraglutide at any meaningful scale in 2026. Demand, and the compounding pharmacies that serve it, has shifted almost entirely to semaglutide and tirzepatide.

Brand liraglutide: Saxenda, Victoza, and their new generics

Saxenda's list price is $1,349 a month, and Novo Nordisk doesn't run a dedicated self-pay program for it the way it does for Wegovy — a GoodRx coupon is the main lever, reportedly bringing it down to roughly $372 a month at some pharmacies, though that figure is worth confirming for your specific pharmacy before counting on it. Victoza, the diabetes-dose brand, runs $1,000 to $1,400 a month at retail; a generic version of that same diabetes dose has been available through GoodRx since mid-2024, ranging $144 to $500 a month depending on pen count and dose — the $144 floor is a starter two-pen package, not a realistic sustained maintenance price, so it's not actually a cheaper long-run option than it looks on paper. Both brands now have generic competition at the weight-loss dose too: in August 2025, Teva launched the first generic GLP-1 approved specifically for weight loss, priced modestly, not dramatically, below brand Saxenda, at roughly $1,165 a month. None of that touches semaglutide's compounded price.

Brand semaglutide self-pay: Wegovy and Ozempic

Novo Nordisk's own cash-pay program is where semaglutide pulls furthest ahead. Wegovy starts as low as $149 to $199 a month on an introductory tier depending on dose and form, settling at $349 a month ongoing. Ozempic, prescribed off-label for weight loss rather than its actual diabetes indication, runs $199 a month introductory, then $349 to $499 depending on the pen strength. Liraglutide has no equivalent manufacturer self-pay ladder to compare against — for an uninsured patient choosing between the two molecules at brand price, semaglutide is the only one with a built-in cash-pay discount program at all.

With insurance and the manufacturer savings card

Here the two molecules converge. If your commercial plan covers Saxenda or Wegovy for a documented weight-management diagnosis, both manufacturer savings cards are built to bring your monthly cost down to around $25. Government insurance — Medicare, Medicaid, TRICARE — is excluded from either card entirely.

What a year actually costs, by pathway

• Compounded semaglutide (Fridays): roughly $1,800–$2,988/yr, depending on prepay length.
• Generic liraglutide, diabetes dose: roughly $2,760–$6,000/yr at a realistic maintenance dose.
• Generic Saxenda, weight-loss dose: roughly $13,980/yr.
• Brand Saxenda, list price: roughly $16,188/yr — about $14,000 a year more than the cheapest compounded semaglutide option above.
• Brand Wegovy self-pay: roughly $3,900/yr, blending the introductory months with the $349/mo ongoing rate.
• Brand Ozempic self-pay (off-label): roughly $3,900–$5,400/yr, depending on maintenance dose.
• Either drug, insured + savings card: roughly $300/yr.

Can I switch from liraglutide to semaglutide?

Yes, and it's a routine switch — this is, in fact, the direction most of the market has already moved. There's no FDA-established dose equivalency between liraglutide and semaglutide, since they're different molecules rather than different strengths of the same drug, so a switch isn't a matter of converting your current daily dose to a matching weekly one. In practice, most prescribers restart semaglutide at its lowest introductory dose rather than trying to match wherever you'd titrated to on liraglutide, and they time the first weekly dose around your last daily injection so there isn't an overlap. How that transition is managed — timing, what to expect in the first few weeks, whether to expect a different side-effect pattern — is worth working through directly with whoever is prescribing.

Side effects — is one easier to tolerate?

Both drugs cause the same family of gastrointestinal side effects, for the same underlying reason: slowing digestion is the mechanism, not a side issue of it. In STEP 8, gastrointestinal adverse events were reported by a similar share of each group — about 84% on semaglutide and 83% on liraglutide — so the overall likelihood of some GI symptom wasn't meaningfully different between the two drugs in that trial. Most events were described as mild to moderate and transient, clustering hardest around dose increases.

Where the drugs may genuinely differ is in how those symptoms feel day to day, tied back to that half-life difference. Liraglutide's daily dosing means any nausea has less time to build before the next dose resets, while semaglutide's weekly injection means a rough patch after dose escalation can stretch out over more of the week before easing. Neither pattern is universal, and which one a given woman tolerates better isn't something trial averages can predict for any one person.

Is compounded semaglutide (or liraglutide) legal and legitimate?

Compounded semaglutide is legal today through a narrower pathway than existed during its 2022–2024 shortage years. That broad shortage was declared resolved in February 2025, which cut off large-scale 503B outsourcing-facility compounding built around the shortage provision. What remains is the 503A individual-patient pathway: a state-licensed compounding pharmacy preparing the medication for one specific, named patient when a prescriber documents a real clinical reason the FDA-approved product won't work — cost alone isn't considered a qualifying reason under current FDA guidance, even though cost is the reason most patients are drawn to it.

Liraglutide's regulatory picture is genuinely murkier and worth naming plainly rather than glossing over. Unlike semaglutide and tirzepatide, liraglutide injection has continued to show up on federal drug-shortage tracking for some presentations even in 2026, which is procedurally different from a resolved shortage. Layered on top, the FDA proposed in April 2026 to exclude semaglutide, tirzepatide, and liraglutide together from the 503B bulk drug substances list, arguing it found no clinical need for outsourcing facilities to compound any of the three — a proposal still working through its public comment period as of this writing, with no final rule issued. In practice, that regulatory ambiguity hasn't translated into a real compounded-liraglutide market: telehealth providers built their compounding pipelines around semaglutide and tirzepatide, and we couldn't verify a legitimate program offering compounded liraglutide at scale.

Separately, both manufacturers have pursued telehealth compounders directly over the past year or so — largely over marketing claims and, in some cases, patent disputes, rather than allegations that the medication itself isn't real. That litigation remains unresolved as of mid-2026. In practical terms, the legitimacy question for compounded semaglutide isn't about the molecule — it's about the specific pharmacy and provider on either side of the transaction. Look for PCAB-accredited pharmacies and a provider willing to explain exactly how they document medical necessity.

Which one is right for you? Verdict by profile

• You've never taken either drug and cost is your main constraint: compounded semaglutide is the cheapest verified path on this page, and it also happens to be the molecule with the stronger average trial result — there's little reason to start with liraglutide on price alone anymore.
• You're already on Victoza or Saxenda and it's working for you: there's no urgent clinical reason to switch just because semaglutide exists — but if a plateau shows up, or the daily injection has become a burden, that's a reasonable moment to ask your provider about semaglutide.
• You have insurance that specifically covers Saxenda or Victoza: let coverage decide before chasing a molecule your plan doesn't pay for — a covered $25/mo liraglutide prescription usually beats an uncovered semaglutide one.
• You want the strongest average result and injection frequency doesn't matter to you: semaglutide's STEP 8 result is the better evidence of the two, roughly double liraglutide's average weight loss in a genuine head-to-head trial.
• A daily routine feels more manageable than remembering a once-a-week shot: this is a real, individual preference some women have — daily liraglutide dosing means less time between a symptom and the chance to adjust with your prescriber, even though the average result is smaller.

Semaglutide vs. liraglutide for perimenopause and menopause weight gain

The weight shift that shows up in perimenopause has a specific hormonal driver: falling estrogen worsens insulin resistance and pushes fat storage toward the abdomen, on top of whatever else is going on in a woman's life at 40-plus. Both liraglutide and semaglutide act on pathways relevant to that shift — improving insulin sensitivity and reducing appetite signaling — which is part of why obesity-medicine physicians increasingly view GLP-1 medications generally as reasonably well matched to the perimenopausal metabolic environment.

No trial has compared liraglutide and semaglutide specifically in a perimenopausal or postmenopausal population, so there isn't a menopause-specific verdict to report between them — STEP 8's head-to-head result above wasn't designed around menopausal status, and it's still the best direct evidence available. For most women in this stage, the more useful real-world question usually isn't which molecule scored higher in a trial: it's whether a GLP-1 medication fits alongside — or instead of — hormone therapy and the other levers available during the transition.